Dr. Scot Ebbinghaus from Merck Research Laboratories discusses Merck’s KEYTRUDA with Inlyta as first-line treatment for advanced renal cell carcinoma.
Dr. Suela Sulo, a study author & health outcomes researcher at Abbott talks about the first-of-its-kind study published in the Journal of Parenteral and Enteral Nutrition.
Dr. Darius Francescatti, a breast surgeon with Rush University Medical Center, discusses the latest technological advances designed to enhance the effectiveness of lumpectomy procedures, including the use of 3D tomography (Kubtec’s Mozart System) in the operating room, and why the 20 percent average re-excision rate for the U.S. is too high.
Dr. Neal D. Shore discusses the FDA approval of NUBEQA® (darolutamide) for the treatment of non-metastatic castration-resistant prostate cancer.
Jim Omel discusses his participation in the INSIGHT MM & the benefits of real-world evidence with patients participating in trials in multiple myeloma.
Dawn Marie Stull PharmD., BCOP scientific director and lead of INSIGHT MM at Takeda Oncology, discusses the INSIGHT MM (multiple myeloma) study, the largest pharmaceutical company-sponsored global observational study of its kind in multiple myeloma.
Shawn Singh, CEO of VistaGen Therapeutics discusses their pipeline which includes nasal sprays that work like spritzers to the brain, for instance, PH10, an experimental antidepressant that completed a phase 2a study and received a patent and PH94B for Social Anxiety Disorder.
Dr. Aswini Misro talks about building a free artificial intelligence application to reduce monopoly in healthcare and to educate the patient.
Dr. Jeff Leighton, a professional pharmacologist, discusses the science behind the newly launched REVIVE, a non-caffeinated energy supplement.